Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NEK5 | Q6P3R8 | 1/20 | 1.00 |
| ▸ | PLK1 | P53350 | 15/20 | 0.71 |
| ▸ | PLK3 | Q9H4B4 | 2/20 | 0.71 |
| ▸ | CDK2 | P24941 | 1/20 | 0.71 |
| ▸ | PTK2 | Q05397 | 2/20 | 0.49 |
| ▸ | JAK2 | O60674 | 1/20 | 0.49 |
| ▸ | INSR | P06213 | 1/20 | 0.49 |
| ▸ | ALK | Q9UM73 | 1/20 | 0.49 |
| ▸ | IGF1R | P08069 | 2/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3994664 | 0.83 | PLK1 (1.00) | NEK5PLK1PLK3CDK2PTK2 | |
| SCHEMBL3994224 | 0.82 | PLK1 (1.00) | NEK5PLK1PLK3CDK2PTK2 | |
| SCHEMBL3994431 | 0.82 | PLK1 (1.00) | NEK5PLK1PLK3CDK2PTK2 | |
| SCHEMBL4127852 | 0.81 | PLK1 (0.73) | NEK5PLK1PLK3CDK2PTK2 | |
| SCHEMBL3994202 | 0.80 | PLK1 (0.83) | NEK5PLK1PLK3CDK2PTK2 | |
| SCHEMBL3991816 | 0.79 | PLK1 (0.71) | NEK5PLK1PLK3CDK2PTK2 | |
| SCHEMBL3992146 | 0.79 | PLK1 (0.68) | NEK5PLK1PLK3CDK2PTK2 | |
| SCHEMBL3994128 | 0.78 | PLK1 (0.71) | NEK5PLK1PLK3CDK2PTK2 | |
| SCHEMBL3994489 | 0.77 | PLK1 (0.75) | NEK5PLK1PLK3CDK2PTK2 | |
| SCHEMBL3995532 | 0.77 | PLK1 (1.00) | NEK5PLK1PLK3CDK2PTK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1608656-B1 | IMIDAZOTRIAZINE COMPOUNDS FOR THE TREATMENT OF CANCER DISEASES | SMITHKLINE BEECHAM CORP (US) | 2009-06-03 | — | — | EP | claimed |
| US-7462614-B2 | Imidazotriazine compounds | SMITHKLINE BEECHAM CORPORATION (US) | 2008-12-09 | — | — | US | claimed |
| US-20060217382-A1 | 7-(2-Bromophenyl)-5-methyl-N-(3,4,5-trimethoxyphenyl)imidazo[5,1-f][1,2,4]triazin-2-amine; to treat neoplasms; polo like kinases inhibitors; antineoplastic/antiproliferative agents; cyclization of 1,2,4-triazine derivatives; coupling if imidazo[5,1-f][1,2,4]triazines with amine or halogen derivatives | SMITHKLINE BEECHAM CORPORATION | 2006-09-28 | — | — | US | claimed |
| EP-1608656-B1 | IMIDAZOTRIAZINE COMPOUNDS FOR THE TREATMENT OF CANCER DISEASES | SMITHKLINE BEECHAM CORP (US) | 2009-06-03 | — | — | EP | disclosed |
| EP-1608656-B1 | IMIDAZOTRIAZINE COMPOUNDS FOR THE TREATMENT OF CANCER DISEASES | SMITHKLINE BEECHAM CORP (US) | 2009-06-03 | — | — | EP | disclosed |
| US-7462614-B2 | Imidazotriazine compounds | SMITHKLINE BEECHAM CORPORATION (US) | 2008-12-09 | — | — | US | disclosed |
| US-7462614-B2 | Imidazotriazine compounds | SMITHKLINE BEECHAM CORPORATION (US) | 2008-12-09 | — | — | US | disclosed |
| US-7462614-B2 | Imidazotriazine compounds | SMITHKLINE BEECHAM CORPORATION (US) | 2008-12-09 | — | — | US | disclosed |
| US-20060217382-A1 | 7-(2-Bromophenyl)-5-methyl-N-(3,4,5-trimethoxyphenyl)imidazo[5,1-f][1,2,4]triazin-2-amine; to treat neoplasms; polo like kinases inhibitors; antineoplastic/antiproliferative agents; cyclization of 1,2,4-triazine derivatives; coupling if imidazo[5,1-f][1,2,4]triazines with amine or halogen derivatives | SMITHKLINE BEECHAM CORPORATION | 2006-09-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060217382-A1 | 7-(2-Bromophenyl)-5-methyl-N-(3,4,5-trimethoxyphenyl)imidazo[5,1-f][1,2,4]triazin-2-amine; to treat neoplasms; polo like kinases inhibitors; antineoplastic/antiproliferative agents; cyclization of 1,2,4-triazine derivatives; coupling if imidazo[5,1-f][1,2,4]triazines with amine or halogen derivatives | PLK2, PLK1, CDKL5 | NEK5 118/4885PLK1 2/4885PLK3 43/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.